Vertex Pharmaceuticals Incorporated's latest marketcap:
As of 06/25/2025, Vertex Pharmaceuticals Incorporated's market capitalization has reached $115.63 B. According to our data, Vertex Pharmaceuticals Incorporated is the 159th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 115.63 B |
| Revenue (ttm) | 11.1 B |
| Net Income (ttm) | -988,900,000 |
| Shares Out | 256.8 M |
| EPS (ttm) | -3.84 |
| Forward PE | 23.87 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/31/2025 |
Vertex Pharmaceuticals Incorporated's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/25/2025 | $115.63 B | 9.17% | 159 |
| 12/31/2024 | $103.71 B | -1.09% | 157 |
| 12/29/2023 | $104.85 B | 41.44% | 132 |
| 12/30/2022 | $74.13 B | 32.76% | 181 |
| 12/31/2021 | $55.83 B | -9.15% | 322 |
| 12/31/2020 | $61.46 B | 9.15% | 242 |
| 12/31/2019 | $56.3 B | 32.95% | 214 |
| 12/31/2018 | $42.35 B | 11.74% | 246 |
| 12/29/2017 | $37.9 B | 107.41% | 327 |
| 12/30/2016 | $18.27 B | -40.9% | 581 |
Company Profile
Vertex Pharmaceuticals Incorporated Overview
Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing innovative therapies for cystic fibrosis (CF) and other serious diseases.
Key Products
- TRIKAFTA/KAFTRIO: For CF patients aged 2+ with at least one F508del mutation.
- ALYFTREK: Treats CF in patients aged 6+.
- SYMDEKO/SYMKEVI: For CF patients aged 6+.
- ORKAMBI: For CF patients aged 1+.
- KALYDECO: Treats CF in patients aged 1 month+ with ivacaftor.
Pipeline & Development
- CASGEVY: For sickle cell disease and transfusion-dependent beta thalassemia.
- JOURNAVX: Targets acute pain in adults.
- VX-522: CFTR mRNA therapeutic (Phase 1/2 trial).
- Inaxaplin: For APOL1-mediated kidney disease (Phase 2 trial).
- VX-880 & VX-264: Treatments for Type 1 Diabetes.
- VX-670: For myotonic dystrophy type 1.
- VX-407: Small molecule corrector for autosomal dominant polycystic kidney disease.
Distribution & Partnerships
Vertex sells its products through specialty pharmacies, distributors, retail pharmacies, hospitals, and clinics in the U.S. The company collaborates with:
- CRISPR Therapeutics AG
- Moderna, Inc.
- Entrada Therapeutics, Inc.
Founded: 1989 | Headquarters: Boston, Massachusetts
Frequently Asked Questions
-
What is Vertex Pharmaceuticals Incorporated's (VRTX) current market cap?As of 06/25/2025, Vertex Pharmaceuticals Incorporated (including the parent company, if applicable) has an estimated market capitalization of $115.63 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Vertex Pharmaceuticals Incorporated (VRTX) rank globally by market cap?Vertex Pharmaceuticals Incorporated global market capitalization ranking is approximately 159 as of 06/25/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.